Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Galectin Therapeutics Inc's Business Segments
Galectin Therapeutics Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
1
Largest Segment
Business Operating Segment
Total Revenue
-
Regions Reported
-
Revenue Share by Reportable Segment - FY
- Business Operating Segment0%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Business Operating Segment | - | - |
Annual Results
Revenue Share by Reportable Segment - FY
- Business Operating Segment0%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Business Operating Segment | - | - |
Description of Galectin Therapeutics Inc
Galectin Therapeutics Inc is a publicly traded, clinical-stage biotechnology company that is focused on developing therapies to treat fibrosis and cancer. In particular, the company is working on developing galectin inhibitors, which are drugs designed to block the activity of galectins, which are proteins involved in inflammation, cell growth, and cell death.
The company was founded in 2000 and is based in Norcross, Georgia. Its lead product candidate is GR-MD-02, a galectin-3 inhibitor that is being developed to treat a variety of fibrotic diseases, including non-alcoholic steatohepatitis (NASH), or fatty liver disease, and liver fibrosis caused by hepatitis C virus (HCV) infection. The company is also exploring the use of galectin inhibitors to treat various types of cancer.
Galectin has completed multiple clinical trials of GR-MD-02 for NASH and liver fibrosis, including a phase 2b clinical trial of GR-MD-02 in patients with NASH cirrhosis. The company is currently conducting a phase 2 clinical trial of GR-MD-02 in combination with KEYTRUDA for the treatment of metastatic melanoma.
In addition to GR-MD-02, Galectin has a pipeline of galectin inhibitors in various stages of development, including GR-α, a galectin-1 inhibitor being developed for the treatment of cancer, and GM-CT-01, a galectin-9 inhibitor being developed for the treatment of asthma and other inflammatory diseases.
Overall, Galectin Therapeutics is focused on developing innovative therapies for serious diseases with unmet medical needs, particularly fibrotic diseases and cancer.
The company was founded in 2000 and is based in Norcross, Georgia. Its lead product candidate is GR-MD-02, a galectin-3 inhibitor that is being developed to treat a variety of fibrotic diseases, including non-alcoholic steatohepatitis (NASH), or fatty liver disease, and liver fibrosis caused by hepatitis C virus (HCV) infection. The company is also exploring the use of galectin inhibitors to treat various types of cancer.
Galectin has completed multiple clinical trials of GR-MD-02 for NASH and liver fibrosis, including a phase 2b clinical trial of GR-MD-02 in patients with NASH cirrhosis. The company is currently conducting a phase 2 clinical trial of GR-MD-02 in combination with KEYTRUDA for the treatment of metastatic melanoma.
In addition to GR-MD-02, Galectin has a pipeline of galectin inhibitors in various stages of development, including GR-α, a galectin-1 inhibitor being developed for the treatment of cancer, and GM-CT-01, a galectin-9 inhibitor being developed for the treatment of asthma and other inflammatory diseases.
Overall, Galectin Therapeutics is focused on developing innovative therapies for serious diseases with unmet medical needs, particularly fibrotic diseases and cancer.
Galectin Therapeutics Inc. is a biotechnology firm dedicated to the discovery and development of innovative therapies that target galectin proteins. These proteins are known to play critical roles in a variety of pathological processes, including fibrosis, cancer, inflammation, and immune disorders. Below is an extensive description of the companys segments, products, and services:
Segments
1. Drug Development:
Galectin Therapeutics focuses on the discovery and commercialization of novel therapeutics that specifically target galectin proteins. This segment primarily emphasizes the development of therapies that aim to address critical health conditions, particularly those related to fibrosis and cancer. The company actively pursues various stages of drug development, from preclinical research to late-stage clinical trials, showcasing a robust pipeline.
2. Research and Development (R&D):
R&D is a cornerstone of Galectin Therapeutics operations. The company is committed to extensive research activities aimed at identifying and validating potential drug targets within the galaxy of galectin proteins. These efforts often involve collaborations with academic institutions, leveraging cutting-edge scientific insights to develop transformative therapies. The R&D segment is essential in advancing the understanding of galectin-mediated mechanisms in disease processes, facilitating the discovery of novel therapeutic strategies.
Products
1. GR-MD-02:
This is the flagship product of Galectin Therapeutics and represents a galectin-3 inhibitor that is currently in clinical development for treating liver fibrosis and non-alcoholic steatohepatitis (NASH). GR-MD-02 has been designed to modulate the immune response and mitigate fibrotic progression by inhibiting galectin-3, which is implicated in fibrotic diseases. Clinical trials are aimed at assessing its efficacy and safety in managing patients with these challenging conditions.
2. GM-CT-01:
GM-CT-01 is another significant asset within the companys portfolio. This galectin-3 inhibitor is in pre-clinical development and is targeted for cancer treatment. The product leverages the understanding of galectin roles in tumor progression and metastasis, aiming to enhance anti-tumor immunity and curb the growth of cancer cells. Preclinical studies are expected to establish its potential therapeutic benefits in oncology.
3. GR-MD-01:
This product also represents a galectin-3 inhibitor and is currently in pre-clinical development for treating pulmonary fibrosis and interstitial lung diseases. The aim is to offer new therapeutic options for patients suffering from chronic lung conditions, wherein galectin-3s role in promoting inflammation and fibrosis presents a compelling target for intervention.
Services
1. Clinical Development:
Galectin Therapeutics provides clinical development services aimed at facilitating the advancement of its drug candidates and those of its collaborators. This service includes the design and execution of clinical trials, data management, and regulatory compliance support, enabling partner organizations to navigate the complexities of bringing novel therapies to market efficiently.
2. Licensing:
The company engages in licensing its technology platforms, drug candidates, and associated patents to other biotech and pharmaceutical entities. This strategic approach not only generates revenue but also fosters collaboration and innovation in the broader biotechnology landscape, allowing other organizations to leverage Galectin Therapeutics proprietary technology.
3. Collaborative Research:
Galectin Therapeutics actively seeks collaborative research opportunities with other biotech companies and academic institutions. These partnerships are designed to combine expertise, share resources, and co-develop therapeutics that target galectins and related pathways. Such collaborative efforts enhance the R&D pipeline and expand the potential applications of galectin-targeted therapies across various diseases.
Conclusion
Galectin Therapeutics Inc. stands out in the biotechnology sector with its concentrated focus on exploring galectin proteins as promising therapeutic targets. With a diverse and innovative product pipeline, dedicated research and development efforts, and a range of services, the company is well-positioned to advance novel treatments for complex diseases like fibrosis and cancer. Its commitment to addressing unmet medical needs through rigorous scientific inquiry and strategic partnerships underscores its potential to become a leader in this specialized area of healthcare.
Segments
1. Drug Development:
Galectin Therapeutics focuses on the discovery and commercialization of novel therapeutics that specifically target galectin proteins. This segment primarily emphasizes the development of therapies that aim to address critical health conditions, particularly those related to fibrosis and cancer. The company actively pursues various stages of drug development, from preclinical research to late-stage clinical trials, showcasing a robust pipeline.
2. Research and Development (R&D):
R&D is a cornerstone of Galectin Therapeutics operations. The company is committed to extensive research activities aimed at identifying and validating potential drug targets within the galaxy of galectin proteins. These efforts often involve collaborations with academic institutions, leveraging cutting-edge scientific insights to develop transformative therapies. The R&D segment is essential in advancing the understanding of galectin-mediated mechanisms in disease processes, facilitating the discovery of novel therapeutic strategies.
Products
1. GR-MD-02:
This is the flagship product of Galectin Therapeutics and represents a galectin-3 inhibitor that is currently in clinical development for treating liver fibrosis and non-alcoholic steatohepatitis (NASH). GR-MD-02 has been designed to modulate the immune response and mitigate fibrotic progression by inhibiting galectin-3, which is implicated in fibrotic diseases. Clinical trials are aimed at assessing its efficacy and safety in managing patients with these challenging conditions.
2. GM-CT-01:
GM-CT-01 is another significant asset within the companys portfolio. This galectin-3 inhibitor is in pre-clinical development and is targeted for cancer treatment. The product leverages the understanding of galectin roles in tumor progression and metastasis, aiming to enhance anti-tumor immunity and curb the growth of cancer cells. Preclinical studies are expected to establish its potential therapeutic benefits in oncology.
3. GR-MD-01:
This product also represents a galectin-3 inhibitor and is currently in pre-clinical development for treating pulmonary fibrosis and interstitial lung diseases. The aim is to offer new therapeutic options for patients suffering from chronic lung conditions, wherein galectin-3s role in promoting inflammation and fibrosis presents a compelling target for intervention.
Services
1. Clinical Development:
Galectin Therapeutics provides clinical development services aimed at facilitating the advancement of its drug candidates and those of its collaborators. This service includes the design and execution of clinical trials, data management, and regulatory compliance support, enabling partner organizations to navigate the complexities of bringing novel therapies to market efficiently.
2. Licensing:
The company engages in licensing its technology platforms, drug candidates, and associated patents to other biotech and pharmaceutical entities. This strategic approach not only generates revenue but also fosters collaboration and innovation in the broader biotechnology landscape, allowing other organizations to leverage Galectin Therapeutics proprietary technology.
3. Collaborative Research:
Galectin Therapeutics actively seeks collaborative research opportunities with other biotech companies and academic institutions. These partnerships are designed to combine expertise, share resources, and co-develop therapeutics that target galectins and related pathways. Such collaborative efforts enhance the R&D pipeline and expand the potential applications of galectin-targeted therapies across various diseases.
Conclusion
Galectin Therapeutics Inc. stands out in the biotechnology sector with its concentrated focus on exploring galectin proteins as promising therapeutic targets. With a diverse and innovative product pipeline, dedicated research and development efforts, and a range of services, the company is well-positioned to advance novel treatments for complex diseases like fibrosis and cancer. Its commitment to addressing unmet medical needs through rigorous scientific inquiry and strategic partnerships underscores its potential to become a leader in this specialized area of healthcare.